Form 8-K ZAFGEN, INC. For: Oct 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Zafgen (ZFGN) PT Cut to $46 at Leerink Partners Amid Partial Clinical Hold; Maintains Bullish View
October 16, 2015 12:07 PM EDTLeerink Partners analyst Joseph Schwartz lowered his price target on Zafgen (NASDAQ: ZFGN) to $46.00 (from $56.00) after the company announced that it received verbal notice from FDA late yesterday that beloranib has been placed on 'partial clinical hold.' However, the analyst is maintaining an Outperform... More
